Real-World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort. (PubMed, Australas J Dermatol) - Oct 18, 2026 - "Adverse events occurred in eight patients (33%), predominantly mild infusion-related reactions, with one fatal pneumonia. These real-world data support planned maintenance after remission rather than single-course rescue use, and prospective multicentre study with standardised severity scoring."
Journal • Real-world evidence • Dermatology • Immunology • Infectious Disease • Pemphigus Vulgaris • Pneumonia • Respiratory Diseases
|
|
Ali Abid; Artiene Tatian; Orli Wargon; Paul Weller; Pokphazz Christjaroon
|